CastleKeep Investment Advisors
NVS icon

CastleKeep Investment Advisors’s Novartis NVS Stock Holding History

CastleKeep Investment Advisors’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
6,792
-501
-7% -$75.1K 0.53% 39
2026
Q1 		$1.11M Sell
7,293
-281
-4% -$43.1K 0.6% 35
2025
Q4 		$1.04M Sell
7,574
-349
-4% -$45.7K 0.47% 57
2025
Q3 		$1.02M Sell
7,923
-3,189
-29% -$389K 0.48% 57
2025
Q2 		$1.34M Sell
11,112
-859
-7% -$96.8K 0.66% 41
2025
Q1 		$1.33M Buy
11,971
+382
+3% +$40.7K 0.69% 47
2024
Q4 		$1.13M Buy
11,589
+1,080
+10% +$115K 0.79% 55
2024
Q3 		$1.21M Buy
10,509
+458
+5% +$52K 0.83% 38
2024
Q2 		$1.07M Sell
10,051
-28
-0.3% -$2.81K 0.83% 30
2024
Q1 		$975K Sell
10,079
-1,069
-10% -$110K 0.7% 48
2023
Q4 		$1.13M Buy
+11,148
New +$1.08M 0.8% 37

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CastleKeep Investment Advisors's NVS Position: Q2 2026 in Review

CastleKeep Investment Advisors reduced its Novartis (NVS) stake by 6.9% in Q2 2026, selling an estimated $75.1K and leaving 6,792 shares worth $1.06M. The position accounts for 0.53% of the portfolio, ranked #39.

CastleKeep Investment Advisors first reported a position in NVS in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.34M in Q2 2025. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • CastleKeep Investment Advisors held 6,792 shares of Novartis worth $1.06M as of Q2 2026.
  • CastleKeep Investment Advisors sold 501 Novartis shares in Q2 2026, an estimated $75.1K.
  • Novartis made up 0.53% of CastleKeep Investment Advisors's portfolio in Q2 2026, its #39 holding.
  • CastleKeep Investment Advisors first reported a position in Novartis in Q4 2023 and has held it in 11 quarters since.
  • CastleKeep Investment Advisors's Novartis position peaked at $1.34M in Q2 2025.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on CastleKeep Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.